Mediamedic/LinkedIn
Sep 29, 2025, 16:19
Xue Feng Presented Her Work on AAV Vector–Based Gene Therapy
Mediamedic shared a post on LinkedIn:
“ISEH 2025 | Professor Xue Feng: AAV Gene Therapy Transforming Hemophilia B Treatment in China
At the 54th Annual Scientific Meeting of ISEH in Kumamoto, Japan, Professor Xue Feng (Institute of Hematology & Blood Diseases Hospital, CAMS) presented her work on AAV vector–based gene therapy expressing Factor IX Padua for Hemophilia B.
In an exclusive interview with Oncology Frontier – Hematology Frontier, she shared the science behind this innovative approach, its clinical potential, and the future of gene therapy development in China.”
Stay updated with Hemostasis Today.
-
Jul 5, 2026, 22:51Shahzaib Akram: What Are We Actually Seeing When a Sickling Test Goes Positive?
-
Jul 5, 2026, 21:474 Tips for Exercising with A Bleeding Disorder – Haemophilia Foundation Australia
-
Jul 5, 2026, 21:06Heghine Khachatryan: Toward Personalized Management of Glanzmann Thrombasthenia
-
Jul 5, 2026, 21:06Priyanka Kumari: IV Fluids and Isotonic Solution
-
Jul 5, 2026, 21:05Ahmed Rizq: Would You Thrombolyse a Stable Patient?
-
Jul 5, 2026, 21:03Emmanuel Obeng Ofori: Diagnosing Anaemia – Why Treating the Root Cause Matters More Than Simply Raising the Haemoglobin
-
Jul 5, 2026, 21:02Mohit Koladia: The Pharmacist’s Role in Stroke Prevention for Atrial Fibrillation
-
Jul 5, 2026, 20:22J. Meireles-Brandao: Exploring the Approach to Thrombophillias
-
Jul 5, 2026, 20:13Kavya Keerthana: The Platelet Count Everyone Calls ‘Reactive’ Until It Isn’t